Compare ResMed Inc. (RMD) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? ResMed Inc. trades at $225 (market cap $32.61B), while Vanguard Real Estate Index Fund ETF trades at $96.4. The key difference: ResMed Inc. pays a 1.17% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | VNQ | |
|---|---|---|
Market Cap | $32.61B | — |
Sector | Health | — |
52-Week High | $293.73 | $100.95 |
52-Week Low | $182.82 | $87.00 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
VNQ, the Vanguard Real Estate ETF, trades at $97.31, up 0.21% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF's financial ratios are not disclosed in the provided data, limiting fundamental assessment. Recent news highlights institutional selling, with firms like City Holding Co. and Bank of America reducing positions, while media comparisons focus on VNQ's U.S. REIT exposure and low fees versus global alternatives.
Outlook remains cautious due to bearish technicals and institutional outflows, though the neutral oscillator reading and upcoming dividend in June 2026 offer some balance. Risks include interest rate sensitivity and real estate market volatility, but the ETF's low expense ratio and diversification provide a defensive income option for long-term investors amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
